Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Descripción del proyecto

Un nuevo dispositivo para la insuficiencia cardíaca diastólica

La insuficiencia cardíaca con fracción de expulsión conservada (ICFEc) es una enfermedad en la que el corazón bombea sangre, pero no se llena de forma adecuada, quizá debido a la rigidez del ventrículo izquierdo. Hoy en día, no existen tratamientos para la disfunción diastólica en la ICFEc, aunque dada la prevalencia de esta afección, se necesitan soluciones con urgencia. En el proyecto CORolla, financiado con fondos europeos, se desarrolló un dispositivo metálico similar a un resorte que se puede implantar en el ventrículo izquierdo del corazón para mejorar su función diastólica en una única intervención quirúrgica. El dispositivo aprovecha la fuerza contráctil del corazón para aumentar el llenado del ventrículo izquierdo.

Objetivo

Heart Failure with preserved ejection fraction (HFpEF) is a life-threatening form of congestive heart failure condition annually affecting more than 25 million people globally. HFpEF occurs commonly in older individuals and has higher prevalence in women. As the European population is aging (over 65 accounting for 19.2% of the total European population, 2.4% more than 10 years ago), HFpEF will affect more and more people, representing significant economic and social challenge for the patients, their families and National Health Systems.

Currently there is no solution on the market for such heart failure condition. Though the effect of some drugs used in the treatment of HF with reduced ejection fraction are currently studied for HFpEF in large clinical trials (e.g. PARAGON-HF Trial, TOPCAT Study), a new approach based on the left interatrial shunting is needed.

The CorAssist introduces a “spring-like” metallic device, CORolla® for augmentation of diastolic function of the heart. The CORolla® is implanted inside the left ventricular of the heart in a minimally invasive procedure. The self-expanding, internal device harnesses the elastic energy during systole (contraction) state and releases it during diastole (relaxation) in order to augment dynamics of left ventricular relaxation and filling. CORolla® manages to impact directly and improve the impaired diastolic function, needing only one-time procedure.

CorAssist Cardiovascular has the vision to become the first company in the world to treat HFpEF. The EC grant is instrumental to this ambitious goal and company’s growth trajectory. Following a very promising validation in animals and humans, the company is planning to start first sales of CORolla® by the end of 2021.The SME Instrument project perfectly aligns with this objective, as it would provide the company with the financial resources necessary to complete the clinical study within the planned time-frame.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-EIC-SMEInst-2018-2020

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

CORASSIST CARDIOVASCULAR LTD
Aportación neta de la UEn
€ 50 000,00
Dirección
114TH MORIYA AVE
3461805 HAIFA
Israel
Pyme
Sí
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00